Citation

Giovanni Schifitto, M.D., Bradford A. Navia, M.D., Constantin Yiannoutsos, Ph.D., Christina M. Marra, M.D., Linda Chang, M.D., Thomas Ernst, Ph.D., Jeffrey G. Jarvik, M.D., M.P.H., Eric N. Miller, Ph.D., Elyse J. Singer, M.D., Ronald J. Ellis, M.D.,Ph.D., Dennis Kolson, M.D., Ph.D., David M. Simpson, M.D., Avindra Nath, M.D., Joseph R. Berger, M.D., Sharon L. Shriver, R.Ph., M.S., Linda L. Millar, B.S., Dodi Colquhoun, M.Sc., Robert Lenkinski, Ph.D., R.Gilberto Gonzalez, M.D., Ph.D., Stuart A. Lipton, M.D., Ph.D. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007 Sep 01; 21(14):1877-86.

Citation

Richard H. Haubrich, M.D., Hongyu Jiang, Ph.D., Ronald Swanstrom, Ph.D., Michael P. Bates, M.D., David Katzenstein, M.D., Leslie A. Petch, Ph.D., Courtney V. Fletcher, Pharm.D., Susan A. Fiscus, Ph.D., Roy (Trip) Gulick, M.D., M.P.H. Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359. HIV Clinical Trials. 2007 Mar 15; 8(2):63-7.

Citation

Jack T. Stapleton, M.D., Kara Bennett, M.S., Ronald J. Bosch, Ph.D., Philip M. Polgreen, Susan Swindells, M.B.B.S. Effect of antiretroviral therapy and hepatitis C co-infection on changes in lipid levels in HIV-infected patients 48 weeks after initiation of therapy. HIV Clinical Trials. 2007 Nov 01; 8(6):429-36.

Citation

Smita A. Kshirsagar, Terrence F. Blaschke, M.D., Lewis Sheiner, M.D., Mizue Krygowski, B.A., Edward P. Acosta, Pharm.D., Davide Verotta, Ph.D. Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria. Journal of Pharmacokinetics & Pharmacodynamics (prev. Journal of Pharmacokinetics and Biopharmaceutics). 2007 Feb 01; 34(1):35-55.